Potent and prolonged hypoglycemic activity of an oral insulin - Tat mixture in diabetic mice

Drug Research

Volumn 63, Issue 7, 2013, Pages 351-356

  Manosroi, J ^a   Tangjai, T ^a   Werner, R G ^b   Gotz F ^b   Manosroi, W ^c   Manosroi, A ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

alloxan induced diabetic mice; hypoglycemic activity; insulin Tat mixture; oral delivery

Indexed keywords

GLUCOSE; HUMAN INSULIN; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; STOMACH JUICE;

EID: 84881258428     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0033-1341422     Document Type: Article

References (29)

1. Shaw J. E., Sicree R. A., Zimmet P. Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract: 2010; 87 4 14
2. World Health Organization Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: 1999; Report No.: WHO/NCD/NCS/992
3. Niswender K. Early and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence? Clin Diabetes: 2009; 27 60 68
4. Snow E. K. (ed.). AHFS Drug Information 2009. Bethesda (MD) American Society of Health - System Pharmacists: 2009
5. th anniversary - an enduring medical miracle. Diabetes Res Clin Pract: 2007; 78 149 158
6. Khafagy E-S, Morishita M., Onuki Y. et al. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliver Rev: 2007; 59 1521 1546
7. Hansen M., Kilk K., Langel Ü. Predicting cell-penetrating peptides. Adv Drug Deliver Rev: 2008; 60 572 579
8. Fonseca S. B., Pereira M. P., Kelley S. O. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliver Rev: 2009; 61 953 964
9. Gupta B., Levchenko T. S., Torchilin V. P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliver Rev: 2005; 57 637 651
10. Brooks H., Lebleu B., Vivès E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliver Rev: 2005; 57 559 577
11. Liang J. F., Yang V. C. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun: 2005; 335 734 738
12. Tangjai T., Manosaroi A., Werner R. G. et al. Hypoglycemic effect improvement of oral human insulin by conjugating with Tat peptide. The Third International Conference on Natural Products for Health and Beauty: 2011; Bangkok, Thailand
13. Deshayes S., Morris M., Heitz F. et al. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv Drug Deliver Rev: 2008; 60 537 547
14. Lohcharoenkal W., Manosaroi A., Götz F. et al. Potent enhancement of GFP uptake into HT-29 cells and rat skin permeation by coincubation with Tat peptide. J Pharm Sci: 2011; 100 4766 4773
15. Manosroi J., Moses Z. Z., Manosroi W. et al. Hypoglycemic activity of Thai medicinal plants selected from the Thai/Lanna Medicinal Recipe Database MANOSROI II. J Ethnopharmacol: 2011; 138 92 98
16. Sun J-E, Ao Z-H, Lu Z-M et al. Antihyperglycemic and antilipidperoxidative effects of dry matter of culture broth of Inonotus obliquus in submerged culture on normal and alloxan-diabetes mice. J Ethnopharmacol: 2008; 118 7 13
17. Christensen S. D., Mikkelsen L. F., Fels J. J. et al. Quality of plasma sampled by different methods for multiple blood sampling in mice. Lab Anim: 2009; 43 65 71
18. The United States Pharmacopeial Convention United States Pharmacopeia (USP) 34 - National Formulary (NF) 29. Rockville (MD) The Convention: 2011
19. Win P. P., Shin-ya Y., Hong K-J et al. Effect of proteolytic enzymes in gastrointestinal fluids on drug release from polyelectrolyte complex microspheres based on partially phosphorylated chitosan. Polym Int: 2005; 54 533 536
20. Makhlof A., Tozuka Y., Takeuchi H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci: 2011; 42 445 451
21. Hu J-W, Liu B. R., Wu C-Y et al. Protein transport in human cells mediated by covalently and noncovalently conjugated arginine-rich intracellular delivery peptides. Peptides: 2009; 30 1669 1678
22. Khafagy E-S, Morishita M., Isowa K. et al. Effect of cell-penetrating peptides on the nasal absorption of insulin. J Control Release: 2009; 133 103 108
23. Lu S-W, Hu J-W, Liu B. R. et al. Arginine-rich intracellular delivery peptides synchronously deliver covalently and noncovalently linked proteins into plant cells. J Agr Food Chem: 2010; 58 2288 2294
24. Lambert D. G. Drugs and receptors. CEACCP: 2004; 4 181 184
25. Farris W., Mansourian S., Chang Y. et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA: 2003; 100 4162 4167
26. Mishra A., Lai G. H., Schmidt N. W. et al. Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc Natl Acad Sci USA: 2011; 108 16883 16888
27. Kararli T. T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos: 1995; 16 351 380
28. El-Andaloussi S., Järver P., Johansson H. et al. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J: 2007; 407 285 292
29. Saar K., Lindgren M., Hansen M. et al. Cell-penetrating peptides: a comparative membrane toxicity study. Anal Biochem: 2005; 345 55 65